Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2006 and is based in Barcelona, Spain.

PANG

EURONEXT:PANG

Pangaea Oncology, S.A.

Last Close

1.79

22/08 10:00

Volume Today

3.81K

Avg: -

PE Ratio

−20.65

PFCF: −15.15

market

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics